WallStreetZenWallStreetZen

NASDAQ: INTS
Intensity Therapeutics Inc Stock Ownership - Who owns Intensity Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Intensity Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Joseph TalamoChief Financial Officer2025-06-3014,179$0.26
$3.70kBuy
John M. WesolowskiPrincipal Accounting Officer2025-06-3069,745$0.26
$18.20kBuy

1 of 1

INTS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when INTS insiders and whales buy or sell their stock.

INTS Shareholders

What type of owners hold Intensity Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Lewis H. Bender3.33%2,000,000$940.00kInsider
Sapient Capital LLC1.63%976,797$459.09kInstitution
Rothschild Wealth LLC0.80%481,184$226.16kInstitution
Geode Capital Management LLC0.43%258,891$121.68kInstitution
Vanguard Group Inc0.43%255,933$120.29kInstitution
Mesirow Financial Investment Management Inc0.33%200,000$94.00kInstitution
Ubs Group Ag0.23%136,232$64.03kInstitution
Brown Advisory Inc0.22%130,072$61.13kInstitution
John M. Wesolowski0.13%76,436$35.92kInsider
Sigma Planning Corp0.12%69,167$32.51kInstitution

1 of 3

INTS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
INTS4.93%3.48%Net Buying
NRXS7.60%23.88%Net Selling
HYPD3.65%96.35%
PLUR0.04%99.96%Net Buying
AKTX0.00%6.24%Net BuyingNet Buying
View Top Biotech Stocks

Intensity Therapeutics Stock Ownership FAQ

Who owns Intensity Therapeutics?

Intensity Therapeutics (NASDAQ: INTS) is owned by 4.93% institutional shareholders, 3.48% Intensity Therapeutics insiders, and 91.59% retail investors. Lewis H. Bender is the largest individual Intensity Therapeutics shareholder, owning 2.00M shares representing 3.33% of the company. Lewis H. Bender's Intensity Therapeutics shares are currently valued at $940.00k.

If you're new to stock investing, here's how to buy Intensity Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.